| Literature DB >> 32274352 |
Nissar Shaikh1, Umais Momin2, Ahmed Atef Shible3, Muna Al-Musalmani4, Abdulla Ansari5.
Abstract
Urosepsis contributes significantly to the epidemiology of sepsis. Urosepsis can be classified as community acquired or hospital acquired, depending upon the origin of infection acquisition: either from the community or from a healthcare facility. A great deal of literature is available about nosocomial urosepsis, but the literature regarding community-acquired urosepsis (CAUs) is limited, and studies are underpowered. The aim of our study was to determine the epidemiology, bacteriology, severity, and outcome of CAUs. Methods and Patients: All patients admitted from the emergency department to the surgical intensive care unit (SICU) with urosepsis over a period of 10 years were identified and included retrospectively from the SICU registry. The study was retrospective. Data were entered into the SPSS program version 23, and groups were compared by using chi-square and t-tests. Results were considered statistically significant at p ≤ 0.05.Entities:
Keywords: Acute respiratory distress syndrome; Arabs; Escherichia coli; acute kidney injury; bacteremia; diabetes mellitus; extended-spectrum beta-lactamase; fever; leukocytosis; oliguria; septic shock; urosepsis
Year: 2020 PMID: 32274352 PMCID: PMC7114219 DOI: 10.5339/qmj.2020.8
Source DB: PubMed Journal: Qatar Med J ISSN: 0253-8253
Descriptive parameters in urosepsis patients at admission.
| Variables | Mean ( ± SD) |
|
| |
| Age (years) | 53.62 ( ± 17.29) |
|
| |
| Duration of ICU stay (days) | 6.47 ( ± 6.69) |
|
| |
| Duration of intubation (days) | 1.69 ( ± 4.17) |
|
| |
| Worst SOFA score | 8.61 ( ± 3.66) |
|
| |
| Temperature (oC) | 38.34 ( ± 1.33) |
|
| |
| Heart rate (beats per minute) | 111.12 ( ± 19.72) |
|
| |
| WBC ( × 103/μL) | 18.48 ( ± 9.06) |
|
| |
| Platelets ( × 103/μL) | 152.45 ( ± 111.29) |
|
| |
| Serum lactate (mmol/L) | 4.44 ( ± 2.77) |
|
| |
| Procalcitonin (ng/mL) | 38.87 ( ± 60.79) |
|
| |
| Prothrombin time (PT) (seconds) | 12.90 ( ± 4.86) |
|
| |
| INR (international normalizing ratio) | 1.32 ( ± 0.47) |
|
| |
| Activated partial thromboplastin time (apTT) (seconds) | 35.98 ( ± 13.90) |
|
| |
| Bilirubin (μmol/L) | 22.43 ( ± 23.47) |
|
| |
Urosepsis and acute kidney injury, interventions, complications, and outcomes.
| Variable | Frequency (n) | Percent (%) | |
|
| |||
| Oliguria | Yes | 152 | 50.3 |
|
| |||
| Acute kidney injury | Yes | 227 | 75.2 |
|
| |||
| Acute renal failure stage 3 | Yes | 86 | 28.5 |
|
| |||
| Renal ureteric stone | Yes | 184 | 60.9 |
|
| |||
| Complications of PCN | Septic shock | 38 | 12.6 |
|
| |||
| Not functioning | 5 | 1.7 | |
|
| |||
| Urological surgery | Endoscopic urological surgery | 75 | 24.8 |
|
| |||
| Lithotripsy | 2 | 0.7 | |
|
| |||
| Nephrectomy | 2 | 0.7 | |
|
| |||
| Severe sepsis septic shock | Severe sepsis | 19 | 6.3 |
|
| |||
| Septic shock | 283 | 93.7 | |
|
| |||
| Transfer or death | Died | 8 | 2.6 |
|
| |||
| Survived | 294 | 97.4 | |
|
| |||
*PCN: percutaneous nephrostomy
Microbiology and use of antibiotics in urosepsis patients.
| Variables | Organism | Frequency | Percent |
|
| |||
| Blood culture | None | 86 | 28.5 |
|
| |||
|
| 45 | 14.9 | |
|
| |||
|
| 99 | 32.8 | |
|
| |||
|
| 18 | 6 | |
|
| |||
|
| 15 | 5 | |
|
| |||
|
| 11 | 3.6 | |
|
| |||
| Other bacteria* | 28 | 9.3 | |
|
| |||
| Blood culture | Negative | 86 | 28.5 |
|
| |||
| Positive | 216 | 71.5 | |
|
| |||
| Urine culture |
| 78 | 25.8 |
|
| |||
|
| 109 | 36.1 | |
|
| |||
|
| 31 | 10.3 | |
|
| |||
|
| 26 | 8.6 | |
|
| |||
| Candida species | 21 | 7 | |
|
| |||
|
| 15 | 5 | |
|
| |||
| Other bacteria* | 22 | 7.3 | |
|
| |||
| Sputum culture | None | 299 | 99 |
|
| |||
|
| 1 | 0.3 | |
|
| |||
|
| 1 | 0.3 | |
|
| |||
| Candida species | 1 | 0.3 | |
|
| |||
| Initial antibiotics | Meropenem | 106 | 35.1 |
|
| |||
| Piperacillin+Tazobactum | 124 | 41.1 | |
|
| |||
| Ceftriaxone | 28 | 9.3 | |
|
| |||
| Ciprofloxacin | 15 | 5 | |
|
| |||
| Ertapenem | 12 | 4 | |
|
| |||
| Other antibiotics* | 17 | 5.6 | |
|
| |||
| Antibiotic change | Meropenem | 106 | 35.1 |
|
| |||
| Piperacillin+Tazobactum | 68 | 22.5 | |
|
| |||
| Ceftriaxone | 25 | 8.3 | |
|
| |||
| Ertapenem | 24 | 7.9 | |
|
| |||
| Other Antibiotics* | 44 | 14.6 | |
|
| |||
* In blood culture: “other bacteria” include Proteus, Candida, E. coli (MDRO), and methicillin sensitive Staphylococcus (MSSA)
* In urine culture: “other bacteria” include Proteus, Enterococcus cloacae, E. coli, K. pneumoniae (MDRO), and methicillin sensitive Staphylococcus (MSSA).
* In initial antibiotics: “other antibiotics” include Ciproflaxacin, Piperacillin+Tazobactum, Meropenam+vancomycin, and Ciprofloxacin+Meropenem.
* In antibiotic change: “other antibiotics” include Colistin, Caspofungin, Amphotericin, Fluconazole, Ciprofloxacin, Piperacillin+Tazobactum, Meropenam+vancomycin, Ciprofloxacin+meropenem, Cloxacillin, Ciprofloxacin, and Anidulafungin.
Urosepsis, bacteraemia, and significant variables.
|
| |||
|
| |||
| Oliguria | |||
|
| |||
| Bacteraemia | No | Yes | 0.001* |
|
| |||
| Negative {Number (%)} | 60(40) | 26(17.1) | |
|
| |||
| Positive {Number (%)} | 90(60) | 126(82.9) | |
|
| |||
| Acute Kidney Injury (AKI) | |||
|
| |||
| Bacteraemia | No | Yes | 0.001* |
|
| |||
| Negative {Number (%)} | 33(44) | 53(23.3) | |
|
| |||
| Positive {Number (%)} | 42(56) | 174(76.7) | |
|
| |||
| Renal Stones | |||
|
| |||
| Bacteraemia | No | Yes | 0.1 |
|
| |||
| Negative {Number (%)} | 39(33.1) | 47(25.5) | |
|
| |||
| Positive {Number (%)} | 79(66.9) | 137(74.5) | |
|
| |||
| Septic Shock | |||
|
| |||
| Bacteraemia | No | Yes | 0.001* |
|
| |||
| Negative {Number (%)} | 16(84.2) | 70(24.70) | |
|
| |||
| Positive {Number (%)} | 3(15.8) | 213(75.3) | |
|
| |||
| Acute respiratory distress syndrome (ARDS) | |||
|
| |||
| Bacteraemia | No | Yes | 0.002* |
|
| |||
| Negative {Number (%)} | 38(44.2) | 70(22.48) | |
|
| |||
| Positive {Number (%)} | 86(65.8) | 216(71.52) | |
|
| |||
*Statistically significant
Urosepsis patients gender and significant variables.
| p value | |||
|
| |||
| Oliguria | |||
|
| |||
| Gender | No | Yes | 0.004* |
|
| |||
| Male {Number (%)} | 63 (42) | 88 (57.9) | |
|
| |||
| Female {Number (%)} | 87 (58) | 64 (42.1) | |
|
| |||
| Acute Kidney injury (AKI) | |||
|
| |||
| Gender | No | Yes | 0.08 |
|
| |||
| Male {Number (%)} | 28 (37.3%) | 123 (54.2) | |
|
| |||
| Female {Number (%)} | 47 (62.7) | 104 (45.8) | |
|
| |||
| Renal Stone | |||
|
| |||
| Gender | No | Yes | 0.45 |
|
| |||
| Male {Number (%)} | 58 (49.2) | 93 (50.5) | |
|
| |||
| Female {Number (%)} | 60 (50.8) | 91 (49.5) | |
|
| |||
| Septic Shock | |||
|
| |||
| Gender | No | Yes | 0.5 |
|
| |||
| Male {Number (%)} | 9 (47.4) | 142 (50.2) | |
|
| |||
| Female {Number (%)} | 10 (52.6) | 141 (49.8) | |
|
| |||
| Intubation | |||
|
| |||
| Gender | No | Yes | 0.042* |
|
| |||
| Male {Number (%)} | 95 (46.3) | 56 (57.7) | |
|
| |||
| Female {Number (%)} | 110 (53.7) | 41 (42.3) | |
|
| |||
| Acute Respiratory Distress syndrome (ARDS) | |||
|
| |||
| Gender | No | Yes | 0.02* |
|
| |||
| Male {Number (%)} | 35 (23.2) | 116 (76.8) | |
|
| |||
| Female {Number (%)} | 51 (33.8) | 100 (66.2) | |
|
| |||
| Bacteraemia | |||
|
| |||
| Gender | No | Yes | 0.027* |
|
| |||
| Male {Number (%)} | 36 (41.9) | 115 (58.1) | |
|
| |||
| Female {Number (%)} | 50 (58.1) | 101 (41.9) | |
|
| |||
*Statistically significant